What should We be making of this?

White coat wearers among us.....your thoughts please

https://www.worldhealth.net/news/rapamycin-prevents-age-related-loss-stem-cells/

I ask, as the title of the paper is

"mTORC1 Activation during Repeated Regeneration Impairs Somatic Stem Cell Maintenance"

Clearly our Board see potential beyond just the cancer space.....we've already got the broad patents....could our drug also be active in this type of thing? ie, mediate the loss of cells due to aging....talk about GINORMOUS if so....perhaps revealing the reasons for Google's [Calico Labs] strong interest in mTOR research?